Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease by Travis, S, Ungaro, R, Blake, A, Bhayat, F, Card, T

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data by Card, T, Ungaro, R, Bhayat, F, Blake, A, Hantsbarger, G, Travis, S

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data by Card, T, Ungaro, R, Bhayat, F, Blake, A, Hantsbarger, G, Travis, S

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM by Yzet, C, Ungaro, R, Bossuyt, P, Baert, F, Vanasek, T, D'Haens, G, Joustra, V, Panaccione, R, Novacek, G, Armuzzi, A, Golovchenko, O, Prymak, O, Goldis, A, Travis, S, Hebuterne, X, Ferrante, M, Rogler, G, Fumery, M, Danese, S, Rydzewska, G, Pariente, B, Hertervig, E, Stanciu, C, Grimaud, J, Diculescu, M, Peyrin-Biroulet, L, Laharie, D, Wright, J, Gomollon, F, Gubonina, I, Schreiber, S, Motoya, S, Hellstrom, P, Halfvarson, J, Colombel, J